4116
明基醫
-0.15 (-0.38%)39.459成交張數15.00本益比1.60股價淨值比5.05%殖利率2026-09-16資料日期
綜合損益表公開資訊觀測站申報原值 · 年度(第 4 季累計) · 每一格 = 該期對去年同期的成長率
營業收入20255,254年增 +10.2%
毛利率202532.2%最新一期
營業利益率20256.5%最新一期
每股盈餘20251.75年增 -25.5%
| 會計項目 | 走勢 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業收入合計 | – | +18.4% | +18.9% | +11.9% | +1.5% | +4.6% | +101.5% | +53.9% | +4.9% | +10.2% | |
| 營業成本合計 | – | +15.3% | +17.1% | +8.5% | +2.0% | +12.1% | +119.6% | +53.0% | +3.7% | +7.4% | |
| 營業毛利（毛損） | – | +24.2% | +22.0% | +17.6% | +0.7% | -7.1% | +67.9% | +56.2% | +7.8% | +16.6% | |
| 未實現銷貨（損）益 | – | – | – | – | – | – | -9.9% | -100.0% | – | – | |
| 已實現銷貨（損）益 | – | – | – | – | – | – | – | – | -100.0% | – | |
| 營業毛利（毛損）淨額 | – | +24.2% | +22.0% | +17.6% | +0.7% | -7.3% | +68.0% | +56.5% | +7.7% | +16.6% | |
| 推銷費用 | – | +55.0% | +39.9% | +15.4% | +4.7% | +5.6% | +52.7% | +65.3% | +14.2% | +22.6% | |
| 管理費用 | – | +9.3% | +0.3% | +19.9% | +6.3% | -2.0% | +48.3% | +3.1% | +12.7% | +16.4% | |
| 研究發展費用 | – | -16.4% | -17.1% | +16.5% | -1.1% | -10.5% | -0.2% | -19.3% | +13.9% | -4.7% | |
| 預期信用減損損失（利益） | – | – | – | – | – | – | -198.1% | – | -57.0% | +863.3% | |
| 營業費用合計 | – | +23.2% | +19.0% | +16.7% | +4.5% | +2.3% | +46.1% | +44.3% | +13.8% | +20.8% | |
| 營業利益（損失） | – | +29.0% | +35.3% | +27.0% | -18.2% | -52.2% | +287.8% | +102.8% | -8.9% | +2.8% | |
| 利息收入 | – | – | – | – | – | -14.1% | +220.8% | +362.1% | +9.9% | +13.5% | |
| 其他收入 | – | -72.7% | +70.2% | -26.5% | +148.5% | +59.2% | +475.9% | -82.0% | -3.2% | +7.7% | |
| 其他利益及損失淨額 | – | -154.0% | – | +17.1% | -248.2% | – | – | -62.8% | +2.7% | +122.8% | |
| 財務成本淨額 | – | +65.8% | +75.8% | +11.8% | -4.7% | -2.6% | +245.2% | +106.9% | +22.5% | +30.4% | |
| 營業外收入及支出合計 | – | -140.7% | – | -82.2% | – | +81.1% | +518.3% | -91.9% | -147.5% | – | |
| 稅前淨利（淨損） | – | +2.4% | +47.7% | +24.1% | -11.4% | -41.5% | +344.9% | +35.7% | -11.7% | +1.6% | |
| 所得稅費用（利益）合計 | – | -11.8% | +19.4% | +23.1% | -4.9% | -40.9% | +200.4% | +187.0% | -16.2% | +26.9% | |
| 繼續營業單位本期淨利（淨損） | – | +7.8% | +56.5% | +24.3% | -13.0% | -41.7% | +382.5% | +11.2% | -9.9% | -8.3% | |
| 本期淨利（淨損） | – | +7.8% | +56.5% | +24.3% | -13.0% | -41.7% | +382.5% | +11.2% | -9.9% | -8.3% | |
| 確定福利計畫之再衡量數 | – | – | -173.6% | – | – | -125.5% | – | -65.4% | +359.9% | -66.0% | |
| 與不重分類之項目相關之所得稅 | – | – | -236.6% | – | – | -125.4% | – | -65.4% | +345.6% | -62.3% | |
| 不重分類至損益之項目： | – | – | – | – | – | -125.5% | – | -65.5% | +363.5% | -66.9% | |
| 國外營運機構財務報表換算之兌換差額 | – | – | – | – | – | – | +232.4% | -138.6% | – | -188.0% | |
| 採用權益法認列之關聯企業及合資之其他綜合損益之份額-可能重分類至損益之項目 | – | – | – | – | – | +35.7% | +165.7% | +281.1% | -100.0% | – | |
| 後續可能重分類至損益之項目： | – | – | – | – | – | +118.4% | +185.5% | +135.9% | +561.7% | -188.0% | |
| 其他綜合損益（淨額） | – | – | -277.8% | – | – | -110.8% | – | -12.3% | +504.3% | -161.1% | |
| 本期綜合損益總額 | – | +21.6% | +47.7% | +26.5% | -9.8% | -43.2% | +390.0% | +11.0% | -5.3% | -16.9% | |
| 母公司業主（淨利∕損） | – | +0.6% | +43.0% | +13.1% | -17.7% | -53.5% | +525.0% | -36.4% | -8.5% | -25.4% | |
| 共同控制下前手權益（淨利∕損） | – | – | – | – | – | – | – | – | -100.0% | – | |
| 非控制權益（淨利∕損） | – | – | +262.1% | +91.9% | +3.9% | -8.5% | +179.0% | +126.6% | +3.7% | +5.3% | |
| 母公司業主（綜合損益） | – | +13.7% | +34.0% | +15.2% | -13.7% | -55.2% | +538.8% | -38.8% | -0.5% | -30.0% | |
| 共同控制下前手權益（綜合損益） | – | – | – | – | – | – | – | – | -100.0% | – | |
| 非控制權益（綜合損益） | – | – | +262.1% | +91.9% | +3.9% | -8.5% | +179.0% | +127.5% | +9.3% | -6.6% | |
| 基本每股盈餘 | – | 0.0% | +42.9% | +12.7% | -17.8% | -53.2% | +521.5% | -36.4% | -8.6% | -25.5% | |
| 稀釋每股盈餘 | – | +1.0% | +41.9% | +12.8% | -17.3% | -53.2% | +518.5% | -36.3% | -8.6% | -25.2% | |
| 採用權益法認列之關聯企業及合資損益之份額淨額 | – | – | – | – | – | -56.8% | +91.9% | +61.4% | -100.0% | – | |
| 其他收益及費損淨額 | – | – | – | – | -100.0% | – | – | – | – | – | |
| 採用權益法認列關聯企業及合資之其他綜合損益之份額-可能重分類至損益之項目 | – | – | – | – | – | – | – | – | – | – |
金額為公司申報原值除以一千(百萬元,四捨五入),每股金額為元。年度為第 4 季的年初至今累計數。走勢條是歷史各期的相對大小,藍為正、綠為負。年增以去年同期為基期,基期非正數或變動超過十倍時不列。 權益變動表在申報資料分頁。